RPSML
Royalty Pharma Sub-Manager, LLC Portfolio holdings
AUM
$171M
This Fund
S&P 500
1 Year Est. Return
–
AUM
$171M
AUM Growth
–
Holding
4
Top Buys
| 1 | +$61M | |
| 2 | +$36.4M | |
| 3 | +$27.8M | |
| 4 |
BCAX
Bicara Therapeutics
BCAX
|
+$21.6M |
Top Sells
No sells this quarter
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Cytokinetics
CYTK
$8.06B
| $62.3M | 36.36% |
+980,392
|
|
||
|
BCAX
2
Bicara Therapeutics
BCAX
$1.39B
| $45.9M | 26.77% |
+1,263,150
|
|
||
3
Biohaven
BHVN
$1.38B
| $33.2M | 19.35% |
+2,936,507
|
|
||
4
BioCryst Pharmaceuticals
BCRX
$2.39B
| $30M | 17.51% |
+3,846,154
|
|